Skip to main content

Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Trial

In brief

Adding anagliptin lowered HbA1c by 0.57 points over 24 weeks

In a trial of 195 Korean adults whose diabetes remained poorly controlled on metformin and empagliflozin, adding anagliptin lowered HbA1c by 0.57 percentage points more than placebo over 24 weeks. More participants reached an HbA1c of 7% or less, and no hypoglycaemic events were reported; the trial does not establish longer-term benefits or safety.

Journal
Diabetes, obesity & metabolism (Q1)
Published
16 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jun Hwa Hong, Young Sang Lyu, Soojin Park, Ho Chan Cho, Kyung Ah Han, Hae Jin Kim, et al.
PMID
43036268
DOI
10.1111/dom.71501

Why clinicians should know about it

  • Picked for Internal Medicine (top studies of the week, 22 November 2026): Randomized trial of add-on therapy for type 2 diabetes

Abstract

AIMS: To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. MATERIALS AND METHODS: In this multicentre, randomised, double-blind, placebo-controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc. RESULTS: The full analysis set included 195 participants (anagliptin, n = 97; placebo, n = 98). At Week 24, LS mean HbA1c changes were -0.81% and -0.24%, respectively, yielding a treatment difference of -0.57% (95% CI -0.74 to -0.40; p < 0.0001). FPG was also significantly reduced (between-group difference -12.15 mg/dL, 95% CI -19.18 to -5.12; p = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37-21.32; p < 0.0001). Treatment-emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported. CONCLUSIONS: Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β-cell function, with acceptable short-term tolerability. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05814406.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.